SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Symphogen A/S Announces Initiation of Phase 2 Trial of Sym004 EGFR Antibody Mixture in Patients with Squamous Cell Carcinoma of Head and Neck Cancer